Matthew Taylor

Assistant Professor

  • 2278 Citations
  • 10 h-Index
20102018
If you made any changes in Pure these will be visible here soon.

Research Output 2010 2018

  • 2278 Citations
  • 10 h-Index
  • 18 Article
  • 1 Comment/debate
Filter
Article
2018
21 Citations

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K. W., Taylor, M., Schöffski, P., Wang, D., Ravaud, A., Gelb, A. B., Xiong, J., Rosen, G., Gulley, J. L. & Apolo, A. B., Jan 1 2018, In : The Lancet Oncology. 19, 1, p. 51-64 14 p.

Research output: Contribution to journalArticle

Platinum
Carcinoma
Neoplasms
Safety
avelumab
47 Citations

Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children

Drilon, A. , Laetsch, T. W. , Kummar, S. , Dubois, S. G. , Lassen, U. N. , Demetri, G. D. , Nathenson, M. , Doebele, R. C. , Farago, A. F. , Pappo, A. S. , Turpin, B. , Dowlati, A. , Brose, M. S. , Mascarenhas, L. , Federman, N. , Berlin, J. , El-Deiry, W. S. , Baik, C. , Deeken, J. , Boni, V. & 18 others Nagasubramanian, R., Taylor, M., Rudzinski, E. R., Meric-Bernstam, F., Sohal, D. P. S., Ma, P. C., Raez, L. E., Hechtman, J. F., Benayed, R., Ladanyi, M., Tuch, B. B., Ebata, K., Cruickshank, S., Ku, N. C., Cox, M. C., Hawkins, D. S., Hong, D. S. & Hyman, D. M., Feb 22 2018, In : New England Journal of Medicine. 378, 8, p. 731-739 9 p.

Research output: Contribution to journalArticle

Fusion Oncogene Proteins
Pyrazoles
Pyrimidines
Kaplan-Meier Estimate
Receptor Protein-Tyrosine Kinases
3 Citations

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

Gambacorti-Passerini, C., Orlov, S., Zhang, L., Braiteh, F., Huang, H., Esaki, T., Horibe, K., Ahn, J. S., Beck, J. T., Edenfield, W. J., Shi, Y., Taylor, M., Tamura, K., Van Tine, B. A., Wu, S. J., Paolini, J., Selaru, P. & Kim, T. M., Jan 1 2018, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Neoplasms
Lymphoma
Confidence Intervals
Safety
1 Citations

Precision targeted therapy with BLU-667 for RET-driven cancers

Subbiah, V. , Gainor, J. F. , Rahal, R. , Brubaker, J. D. , Kim, J. L. , Maynard, M. , Hu, W. , Cao, Q. , Sheets, M. P. , Wilson, D. , Wilson, K. J. , Dipietro, L. , Fleming, P. , Palmer, M. , Hu, M. I. , Wirth, L. , Brose, M. S. , Ou, S. H. I. , Taylor, M. , Garralda, E. & 5 others Miller, S., Wolf, B., Lengauer, C., Guzi, T. & Evans, E. K., Jul 1 2018, In : Cancer Discovery. 8, 7, p. 836-849 14 p.

Research output: Contribution to journalArticle

Transfection
Neoplasms
Thyroid Neoplasms
Therapeutics
Non-Small Cell Lung Carcinoma
3 Citations

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

Kelly, K., Infante, J. R., Taylor, M. H., Patel, M. R., Wong, D. J., Iannotti, N., Mehnert, J. M., Loos, A. H., Koch, H., Speit, I. & Gulley, J. L., Jan 1 2018, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

Clinical Trials
Safety
Neoplasms
avelumab
CD274 Antigen

Signature program: A platform of basket trials

Slosberg, E. D., Kang, B. P., Peguero, J., Taylor, M., Bauer, T. M., Berry, D. A., Braiteh, F., Spira, A., Meric-Bernstam, F., Stein, S., Piha-Paul, S. A. & Salvado, A., Apr 20 2018, In : Oncotarget. 9, 30, p. 21383-21395 13 p.

Research output: Contribution to journalArticle

Neoplasms
Mutation
Hematologic Neoplasms
Clinical Studies
Therapeutics
2017
2 Citations

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

Kiyota, N., Robinson, B., Shah, M., Hoff, A. O., Taylor, M. H., Li, D., Dutcus, C. E., Lee, E. K., Kim, S. B. & Tahara, M., Sep 1 2017, In : Thyroid : official journal of the American Thyroid Association. 27, 9, p. 1135-1141 7 p.

Research output: Contribution to journalArticle

Thyroid Neoplasms
Safety
Placebos
Disease Progression
Confidence Intervals
19 Citations

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors

Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., Sikic, B. I., Taylor, M. H., Northfelt, D. W., Carson, W. E., Hawthorne, T. R., Davis, T. A., Yellin, M. J., Keler, T. & Bullock, T., Jun 20 2017, In : Journal of Clinical Oncology. 35, 18, p. 2028-2036 9 p.

Research output: Contribution to journalArticle

Anti-Idiotypic Antibodies
Safety
Neoplasms
T-Lymphocytes
Disease-Free Survival
2016
10 Citations

Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer

Robinson, B., Schlumberger, M., Wirth, L. J., Dutcus, C. E., Song, J., Taylor, M. H., Kim, S. B., Krzyzanowska, M. K., Capdevila, J., Sherman, S. I. & Tahara, M., Nov 1 2016, In : Journal of Clinical Endocrinology and Metabolism. 101, 11, p. 4103-4109 7 p.

Research output: Contribution to journalArticle

Thyroid Neoplasms
Tumors
Neoplasms
Disease-Free Survival
Placebos
219 Citations

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Hodi, F. S. , Chesney, J. , Pavlick, A. C. , Robert, C. , Grossmann, K. F. , McDermott, D. F. , Linette, G. P. , Meyer, N. , Giguere, J. K. , Agarwala, S. S. , Shaheen, M. , Ernstoff, M. S. , Minor, D. R. , Salama, A. K. , Taylor, M. H. , Ott, P. A. , Horak, C. , Gagnier, P. , Jiang, J. , Wolchok, J. D. & 1 others Postow, M. A., Nov 1 2016, In : The Lancet Oncology. 17, 11, p. 1558-1568 11 p.

Research output: Contribution to journalArticle

Melanoma
Survival
nivolumab
ipilimumab
Colitis
247 Citations

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial

Antonia, S. J. , López-Martin, J. A. , Bendell, J. , Ott, P. A. , Taylor, M. , Eder, J. P. , Jäger, D. , Pietanza, M. C. , Le, D. T. , de Braud, F. , Morse, M. A. , Ascierto, P. A. , Horn, L. , Amin, A. , Pillai, R. N. , Evans, J. , Chau, I. , Bono, P. , Atmaca, A. , Sharma, P. & 4 others Harbison, C. T., Lin, C. S., Christensen, O. & Calvo, E., 2016, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
nivolumab
ipilimumab
Therapeutics
Platinum
6 Citations

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

Graff, J. N., Higano, C. S., Hahn, N. M., Taylor, M. H., Zhang, B., Zhou, X., Venkatakrishnan, K., Leonard, E. J. & Sarantopoulos, J., Aug 15 2016, In : Cancer. 122, 16, p. 2524-2533 10 p.

Research output: Contribution to journalArticle

docetaxel
Aurora Kinase A
Neoplasms
Pharmacokinetics
Fever
2 Citations

Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

Gianoukakis, A. G., Flores, N. M., Pelletier, C. L., Forsythe, A., Wolfe, G. R. & Taylor, M. H., May 30 2016, In : Cancer Management and Research. 8, p. 67-76 10 p.

Research output: Contribution to journalArticle

Patient Acceptance of Health Care
Health Resources
Thyroid Neoplasms
Iodine
Health
2015
24 Citations

Fibroblast Growth Factor Signaling Controls Liver Size in Mice with Humanized Livers

Naugler, W. E., Tarlow, B. D., Fedorov, L. M., Taylor, M., Pelz, C., Li, B., Darnell, J. & Grompe, M., Sep 1 2015, In : Gastroenterology. 149, 3, p. 728e15-740e15

Research output: Contribution to journalArticle

Fibroblast Growth Factors
Bile Acids and Salts
Liver
Hepatocytes
Body Weight
326 Citations

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer

Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., Gianoukakis, A. G., Kiyota, N., Taylor, M. H., Kim, S. B., Krzyzanowska, M. K., Dutcus, C. E., De Las Heras, B., Zhu, J. & Sherman, S. I., Feb 12 2015, In : New England Journal of Medicine. 372, 7, p. 621-630 10 p.

Research output: Contribution to journalArticle

Thyroid Neoplasms
Placebos
Iodine
Disease-Free Survival
Survival Rate
1121 Citations

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A. , Chesney, J. , Pavlick, A. C. , Robert, C. , Grossmann, K. , McDermott, D. , Linette, G. P. , Meyer, N. , Giguere, J. K. , Agarwala, S. S. , Shaheen, M. , Ernstoff, M. S. , Minor, D. , Salama, A. K. , Taylor, M. , Ott, P. A. , Rollin, L. M. , Horak, C. , Gagnier, P. , Wolchok, J. D. & 1 others Hodi, F. S., May 21 2015, In : New England Journal of Medicine. 372, 21, p. 2006-2017 12 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Poisons
ipilimumab
nivolumab
2014
7 Citations

Medical Therapy for Advanced Forms of Thyroid Cancer

Rajhbeharrysingh, U., Taylor, M. & Milas, M., 2014, In : Surgical Clinics of North America. 94, 3, p. 541-571 31 p.

Research output: Contribution to journalArticle

Local Neoplasm Recurrences
Molecular Targeted Therapy
Adjuvant Radiotherapy
Thyroid Neoplasms
Antineoplastic Agents
2010
220 Citations

The ploidy conveyor of mature hepatocytes as a source of genetic variation

Duncan, A. W., Taylor, M. H., Hickey, R. D., Hanlon Newell, A. E., Lenzi, M. L., Olson, S. B., Finegold, M. J. & Grompe, M., Oct 7 2010, In : Nature. 467, 7316, p. 707-710 4 p.

Research output: Contribution to journalArticle

Ploidies
Hepatocytes
Polyploidy
Chromosomes
Artificial Cells